Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhuoran Yao

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Biochimica Et Biophysica Acta. Reviews on Cancer|December 26, 2024
Nervous system contributions to small cell lung cancer: Lessons from diverse oncological studiesShuangsi Liao, Kai Kang, Zhuoran Yao, et al.
Cancer Letters|May 21, 2023
Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapyKai Kang, Yijun Wu, Zhuoran Yao, et al.
Cell Reports. Medicine|August 28, 2025
Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategiesKai Kang, Shanghai Liu, Zhuoran Yao, et al.
Clinical Immunology (Orlando, Fla.)|March 6, 2020
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulationHuaxia Yang, Zhuoran Yao, Xiaoxiang Zhou, et al.
Frontiers in Immunology|March 13, 2026
Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targetingHui Wang, Zhuoran Yao, Ren Luo, et al.
Cancer Medicine|March 23, 2023
Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysisGuo Lin, Zhuoran Yao, Kai Kang, et al.
Journal of Translational Medicine|April 17, 2025
Dynamic evolution and antitumor mechanisms of CXCR6<sup>+</sup>CD8<sup>+</sup> T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapyGuo Lin, Zhuoran Yao, Kai Kang, et al.
BMC Medicine|April 21, 2020
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysisXiaoxiang Zhou, Zhuoran Yao, Huaxia Yang, et al.
Frontiers in Immunology|November 28, 2022
Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancerYijun Wu, Zhuoran Yao, Jianhui Zhang, et al.
Frontiers in Oncology|June 20, 2022
Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and TherapiesYue Zheng, Laduona Wang, Limei Yin, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Biochimica Et Biophysica Acta. Reviews on Cancer|December 26, 2024
Nervous system contributions to small cell lung cancer: Lessons from diverse oncological studiesShuangsi Liao, Kai Kang, Zhuoran Yao, et al.
Cancer Letters|May 21, 2023
Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapyKai Kang, Yijun Wu, Zhuoran Yao, et al.
Cell Reports. Medicine|August 28, 2025
Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategiesKai Kang, Shanghai Liu, Zhuoran Yao, et al.
Clinical Immunology (Orlando, Fla.)|March 6, 2020
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulationHuaxia Yang, Zhuoran Yao, Xiaoxiang Zhou, et al.
Frontiers in Immunology|March 13, 2026
Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targetingHui Wang, Zhuoran Yao, Ren Luo, et al.
Cancer Medicine|March 23, 2023
Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysisGuo Lin, Zhuoran Yao, Kai Kang, et al.
Journal of Translational Medicine|April 17, 2025
Dynamic evolution and antitumor mechanisms of CXCR6<sup>+</sup>CD8<sup>+</sup> T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapyGuo Lin, Zhuoran Yao, Kai Kang, et al.
BMC Medicine|April 21, 2020
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysisXiaoxiang Zhou, Zhuoran Yao, Huaxia Yang, et al.
Frontiers in Immunology|November 28, 2022
Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancerYijun Wu, Zhuoran Yao, Jianhui Zhang, et al.
Frontiers in Oncology|June 20, 2022
Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and TherapiesYue Zheng, Laduona Wang, Limei Yin, et al.
Pageof 4